
Lipocine (LPCN) Stock Forecast & Price Target
Lipocine (LPCN) Analyst Ratings
Bulls say
Lipocine Inc. is advancing its portfolio of proprietary oral drug delivery solutions, with LPCN 1154 showing promising data, including a rapid onset of action and a high remission rate of up to 61% within three days alongside a favorable safety profile. The company is on track to potentially submit a 505(b)(2) new drug application for LPCN 1154, which could significantly enhance its market presence and revenue potential. Despite reporting a minor net loss of $3.2 million, the increased probability of LPCN 1154's approval strengthens the company's growth outlook, signaling a positive trajectory for its financial performance.
Bears say
Lipocine Inc reported a net loss of $3.2 million in the third quarter of 2025, indicating continued financial strain as the company invests in costly research and development efforts. Additionally, the outlook for LPCN 1154 is fraught with uncertainty, as it faces multiple risks including the potential failure in clinical trials, challenges in obtaining regulatory approval, and hurdles in achieving commercial success due to market dynamics. The presence of dilution risk further exacerbates the company's financial challenges, highlighting concerns over long-term investor value and stock performance.
This aggregate rating is based on analysts' research of Lipocine and is not a guaranteed prediction by Public.com or investment advice.
Lipocine (LPCN) Analyst Forecast & Price Prediction
Start investing in Lipocine (LPCN)
Order type
Buy in
Order amount
Est. shares
0 shares